Relevant bibliographies by topics / Cholinesterase; Alzheimer's disease / Dissertations / Theses
To see the other types of publications on this topic, follow the link: Cholinesterase; Alzheimer's disease.

Dissertations / Theses on the topic 'Cholinesterase; Alzheimer's disease'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 40 dissertations / theses for your research on the topic 'Cholinesterase; Alzheimer's disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Giles, Kurt. "Post-translational modifications of acetylcholinesterase." Thesis, University of Oxford, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yau, Kenneth Kwok-Chi. "Assessing and predicting treatment responses to cholinesterase inhibitor pharmacotherapy in Alzheimer's disease." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0015/MQ54172.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Connelly, Stephen. "Studies on pyroglutamyl carboxyl peptidase enzymes and cholinesterase inhibitors : implications for Alzheimer's disease." Thesis, University of Exeter, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.430098.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Spowart-Manning, Laura. "The evaluation of behavioural tasks and animal models of Alzheimer's disease for assessing putative cognition enhancers, using a cholinesterase inhibitor as reference compound." Thesis, University of Bristol, 2001. http://hdl.handle.net/1983/09e768fe-f64c-47c0-b4d4-d0a19b8ff23d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Foka, Germaine Boulenoue. "Synthesis and evaluation of novel coumarin-donepezil derivatives as dual acting monoamine oxidase B and cholinesterase in Alzheimer's disease." University of the Western Cape, 2016. http://hdl.handle.net/11394/5549.

Full text
Abstract:
Magister Pharmaceuticae - MPharm<br>Alzheimer's disease is a progressive neurodegenerative disease characterised by low acetylcholine (ACh) levels in the hippocampus and cortex of the brain, causing symptoms like progressive memory loss, decline in language skills and other cognitive impairments to occur. The hallmarks of AD include the presence of extracellular insoluble amyloid beta plaques, intracellular neurofibrillary tangles, and the decrease in ACh concentration. The pathophysiology of AD is not well understood, however, acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and mon
APA, Harvard, Vancouver, ISO, and other styles
6

Svensson, Anne-Lie. "Cholinesterase inhibitors in Alzheimer's disease : an experimental study on mechanisms of interaction with muscarinic and nicotinic receptors and neuroprotection /." Stockholm, 1997. http://diss.kib.ki.se/1997/91-628-2733-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Anderholm, Louise. "Behandling av beteendemässiga ochpsykiska symtom med fokus påagitation hos äldre med Alzheimerssjukdom. : En jämförelse mellan neuroleptika ochacetylkolinesterashämmare." Thesis, Umeå universitet, Farmakologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-119733.

Full text
Abstract:
Inledning: År 2030 uppskattas det vara ungefär 230 000 stycken människor i Sverige somhar drabbats av någon typ av demenssjukdom. Sjukdomens stadier delas in i begynnande,mild, måttlig och svår demens. Där första symtomen i den begynnande fasen brukar vara attden drabbade inte kommer ihåg vart den lagt sina saker. I den svåra fasen av sjukdomen ärpatienten förmodligen beroende av dygnet runt vård, patienten brukar även ha svårt attprata, enstaka ord eller meningar brukar upprepas. Beteendemässiga och psykiska symtom(BPSD) hos demenssjuka är symtom som kan orsaka lidande hos patienten och dessa
APA, Harvard, Vancouver, ISO, and other styles
8

Forsström, Karin. "Longitudinal Changes in Astroglial and Inflammatory Markers in Patients with MCI and AD." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-192975.

Full text
Abstract:
Since neuroinflammation is present in patients with mild cognitive impairment (MCI) andAlzheimer's disease (AD) and since cholinesterase inhibitors increases the level ofacetylcholine, the aim was to investigate whether inflammatory markers of cholinoceptive cellsare affected in these patients. Near a biological hallmark of AD, amyloid plaque, activatedastrocytes and microglia can be found and higher levels of proinflammatory cytokines, i.e. IL-1β. To study the inflammatory response, proteins GFAP and S100B are used as CSF glialmarkers. IL-1β can bind to the membrane-bound IL-1 receptor or sol
APA, Harvard, Vancouver, ISO, and other styles
9

Navaratnam, Dasakumar Selveraj. "Cholinesterases in Alzheimer's disease." Thesis, University of Oxford, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306734.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blanco, Silvente Lídia. "La relación beneficio-riesgo del tratamiento farmacológico para la enfermedad de Alzheimer." Doctoral thesis, Universitat de Girona, 2019. http://hdl.handle.net/10803/667938.

Full text
Abstract:
The evidence available in the medical literature is conclusive that the risk-benefit relationship of the current medications for Alzheimer's disease is not favourable. This risk-benefit relationship is not significantly modified by any factor related to the design of the clinical trials, neither with the intervention nor with patient’s characteristics. It is also important to highlight that redundant studies that do not provide new evidence have been identified, so the realization of new clinical trials to evaluate the efficacy and safety of current medications for Alzheimer's disease would be
APA, Harvard, Vancouver, ISO, and other styles
11

Benchekroun, Mohamed. "Synthèse multicomposants et évaluation pharmacologique de nouveaux adduits de Ugi et de Passerini pour le traitement de la maladie d'Alzheimer." Thesis, Besançon, 2014. http://www.theses.fr/2014BESA3007/document.

Full text
Abstract:
La maladie d'Alzheimer est la pathologie neurodégénérative la plus courante affectant les personnes âgées. Cette neuropathologie se caractérise par une étiologie complexe dont le déficit en acétylcholine, les plaques amyloïdes, les dégénérescences neurofibrillaires ou le stress oxydant en sont les principaux acteurs.Au cours de cette thèse, nous nous sommes intéressés à l'application des réactions multicomposants de Ugi et de Passerini, pour la synthèse de nouveaux adduits multi-cibles basées sur différents motifs antioxydants et anticholinestérasiques. Ces réactions permettent d'accéder à une
APA, Harvard, Vancouver, ISO, and other styles
12

Torres, Juliana Mariano. "Estudo cin?tico da atividade anticolinester?sica de derivados ?- Carbol?nicos do produto natural harmana." Universidade Federal Rural do Rio de Janeiro, 2011. https://tede.ufrrj.br/jspui/handle/jspui/1144.

Full text
Abstract:
Submitted by Sandra Pereira (srpereira@ufrrj.br) on 2016-08-01T17:07:57Z No. of bitstreams: 1 2011 - Juliana Mariano Torres.pdf: 1156662 bytes, checksum: 6ae713d0002e13c804fc2eba73bd8f5b (MD5)<br>Made available in DSpace on 2016-08-01T17:07:57Z (GMT). No. of bitstreams: 1 2011 - Juliana Mariano Torres.pdf: 1156662 bytes, checksum: 6ae713d0002e13c804fc2eba73bd8f5b (MD5) Previous issue date: 2011-07-22<br>Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico, CNPq.<br>The increase in life expectancy is a worldwide occurrence that shows the relative success of public health politics, a
APA, Harvard, Vancouver, ISO, and other styles
13

Daltin, Jussemi Biazon [UNESP]. "Uso de medicamentos em pacientes idosos portadores de doença de Alzheimer." Universidade Estadual Paulista (UNESP), 2016. http://hdl.handle.net/11449/145031.

Full text
Abstract:
Submitted by JUSSEMI BIAZON DALTIN null (jussemidaltin@bauru.sp.gov.br) on 2016-12-07T00:06:46Z No. of bitstreams: 1 Dissertacao de Mestrado - Jussemi.pdf: 2697527 bytes, checksum: a495bff84c4ebd015c2fa73b1fa5fb53 (MD5)<br>Approved for entry into archive by Felipe Augusto Arakaki (arakaki@reitoria.unesp.br) on 2016-12-09T13:03:08Z (GMT) No. of bitstreams: 1 daltin_jb_me_bot.pdf: 2697527 bytes, checksum: a495bff84c4ebd015c2fa73b1fa5fb53 (MD5)<br>Made available in DSpace on 2016-12-09T13:03:08Z (GMT). No. of bitstreams: 1 daltin_jb_me_bot.pdf: 2697527 bytes, checksum: a495bff84c4ebd015c2fa73
APA, Harvard, Vancouver, ISO, and other styles
14

Darreh-Shori, Taher. "Molecular changes of acetylcholinesterase and butyrylcholinesterase in Alzheimer patients during the natural couse of the disease and treatment with cholinesterase inhibitors : insight into neurochemical mechanisms affecting the progression of the disease /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-547-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Bolea, Tomás Irene. "Study of new propargylamine and donepezil-derived compounds as multitarget agents for the treatment of alzheimer’s disease." Doctoral thesis, Universitat Autònoma de Barcelona, 2011. http://hdl.handle.net/10803/79083.

Full text
Abstract:
El compuesto PF9601N es un derivado de propargilamina y un potente inhibidor irreversible de la enzima monoamino oxidasa B (IMAO-B) el cual fue identificado por nuestro grupo tras una extensiva búsqueda de potenciales IMAOs. Además de su potente capacidad inhibidora, el PF9601N posee varias propiedades neuroprotectoras demostradas en varios modelos animales y celulares de la enfermedad de Parkinson (EP). Estos efectos, los cuales han sido relacionados con la presencia de la propargilamina en su estructura, están mediados por acciones en vías involucradas en la neurodegeneración observada en ot
APA, Harvard, Vancouver, ISO, and other styles
16

Teponnou, Gerard A. Kenfack. "Tacrine, trolox and tryptoline as lead compounds for the design and synthesis of multi-target drugs for Alzheimer's disease therapy." Thesis, University of the Western Cape, 2016. http://hdl.handle.net/11394/5344.

Full text
Abstract:
Magister Pharmaceuticae - MPharm<br>The cascade of neurotoxic events involved in the pathogenesis of Alzheimer's disease may explain the inefficacy of currently available treatment based on acetylcholinesterase inhibitors (AChEI - donepezil, galantamine, rivastigmine) and N-methyl-D-aspartate (NMDA) antagonists (memantine). These drugs were designed based on the "one-moleculeone- target" paradigm and only address a single target. Conversely, the multi-target drug design strategy increasingly gains recognition. Based on the versatile biological activities of tacrine, trolox and β-carboline deri
APA, Harvard, Vancouver, ISO, and other styles
17

Mzezewa, Sheunopa C. "Synthesis and evaluation of 7-substituted 3-propargylamine coumarin derivatives as multifunctional monoamine oxidase and cholinesterase inhibitors for Alzheimer’s Disease treatme." University of Western Cape, 2020. http://hdl.handle.net/11394/7399.

Full text
Abstract:
>Magister Scientiae - MSc<br>Alzheimer’s Disease (AD) is a neurodegenerative disease which results from the irreversible loss of neurons in the brain. The disease is characterized by progressive cognitive impairment with recurrent short-term memory loss. AD is the leading cause of dementia and 4th leading cause of death in the elderly. Success in the treatment of AD has been limited, with drugs only treating it at a symptomatic level due to its pathology being complex and poorly understood. However, it is known that the cholinesterase and MAO-B enzymes play an important role in the disease thr
APA, Harvard, Vancouver, ISO, and other styles
18

Kadir, Ahmadul. "Functional brain activity in Alzheimer patients as studied by multi-tracer positron emission tomography : effects of treatment with cholinesterase inhibitors /." Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-357-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Toublet, Francois-Xavier. "Conception, synthèse et évaluation biologique de prodrogues pléiotropes d'intérêt dans la maladie d'Alzheimer." Thesis, Normandie, 2019. http://www.theses.fr/2019NORMC429.

Full text
Abstract:
La maladie d’Alzheimer (MA) est une maladie neurodégénérative multifactorielle encore mal comprise. Les médicaments actuellement utilisés contre la MA, principalement des inhibiteurs de cholinestérases (IChE), sont considérés comme ayant un service médical rendu insuffisant et sont responsables d’effets secondaires délétères. Les ChE suscitent toutefois un regain d’intérêt grâce à la découverte du rôle de chaperon joué dans la pathogenèse de la MA. Ces enzymes pourraient également servir de protéine d'activation pour les promédicaments pléiotropes. En effet, l'inhibition des ChE centrales par
APA, Harvard, Vancouver, ISO, and other styles
20

Bitencourt, Michelle 1985. "Modelagem MIA-QSAR de inibidores de acetilcolinesterase = MIA-QSAR modeling of inhibitors actylcholinesterase." [s.n.], 2012. http://repositorio.unicamp.br/jspui/handle/REPOSIP/311808.

Full text
Abstract:
Orientador: Roberto Rittner Neto<br>Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas<br>Made available in DSpace on 2018-08-21T10:40:13Z (GMT). No. of bitstreams: 1 Bitencourt_Michelle_M.pdf: 771721 bytes, checksum: 1771939b9c0680c7375ae9953fca996f (MD5) Previous issue date: 2012<br>Resumo: O presente trabalho trata de um estudo sobre compostos que se comportam como inibidores da acetilcolinesterase, uma importante enzima do processo de cognição. A acetilcolinesterase atua na hidrólise da acetilcolina, responsável pela comunicação entre os neurônios.
APA, Harvard, Vancouver, ISO, and other styles
21

Talib, Leda Leme. "Biomarcadores na doença de Alzheimer: GSK3B e PLA2 na resposta aos inibidores de colinesterase." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5142/tde-24062014-163102/.

Full text
Abstract:
A Doença de Alzheimer (DA) é uma desordem neurodegenerativa progressiva que causa comprometimento cognitivo e demência. O diagnóstico é baseado em parâmetros clínicos, mas sua confirmação é post-mortem, após avaliação patológica durante a autópsia. Os tratamentos disponíveis para a DA são os inibidores da colinesterase (IChEs) e os antagonistas de receptores de N-metil-D-aspartato (NMDA), sendo que os IChEs compõe o principal grupo. Diversos estudos tem mostrado um efeito neuroprotetor dos IChEs, levando a alterações na patogênese da DA. Avaliar e mensurar essas alterações são papeis atribuído
APA, Harvard, Vancouver, ISO, and other styles
22

Sarno, Tamires Alves. "Efeito de inibidor da acetilcolinesterase no metabolismo da proteína precursora do amiloide em plaquetas." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5142/tde-18112016-112848/.

Full text
Abstract:
A doença de Alzheimer (DA) é uma doença neurodegenerativa e a principal causa de demência em idosos. Os mecanismos fisiopatológicos mais envolvidos na DA são: o acúmulo do peptídeo beta amiloide (A?) em agregados extracelulares, e a formação dos emaranhados neurofibrilares (ENF). A Proteína Precursora do Amiloide (APP) é clivada pelas secretases alfa (ADAM10), beta (BACE1) e y (Presenilina 1 [PSEN1]). As plaquetas contêm 95% da APP circulante e possuem toda a maquinaria necessária para estudar perifericamente a APP e suas secretases. A pesquisa de biomarcadores na DA tem como objetivo identifi
APA, Harvard, Vancouver, ISO, and other styles
23

Piovesana, Magda Cristina Flaitt Sanches. "Doença de Alzheimer: estudos sobre acurácia diagnóstica nos pacientes em uso de anticolinesterásicos e a percepção dos familiares quanto aos seus benefícios." Faculdade de Medicina de São José do Rio Preto, 2010. http://bdtd.famerp.br/handle/tede/93.

Full text
Abstract:
Made available in DSpace on 2016-01-26T12:51:28Z (GMT). No. of bitstreams: 1 magdacristinaflaittsanchespiovesana_dissert.pdf: 1394131 bytes, checksum: c999c1d2fcb99fa0db69afa796196ce4 (MD5) Previous issue date: 2010-12-03<br>This study was realized in the Neurogeriatrics Clinic Base Hospital of Medicine Faculty in Sao Jose do Rio Preto. Objective: To study the diagnostic accuracy in Alzheimer's disease in patients treated with cholinesterase inhibitors available by Pharmacy of Exceptional Medicines and verify the impact of this therapy by the perception of families or caregivers. Methods: Cr
APA, Harvard, Vancouver, ISO, and other styles
24

Ávila, Renata. ""Reabilitação neuropsicológica dos processos de memória e das atividades da vida diária em pacientes com doença de Alzheimer leve e moderada"." Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5160/tde-24082005-150424/.

Full text
Abstract:
O efeito da reabilitação neuropsicológica foi verificado em uma amostra de 16 pacientes com diagnóstico de doença de Alzheimer leve e moderado. Após ensaio clínico aberto com rivastigmina por 4 meses, os pacientes foram divididos em três grupos: sessões em grupo, individual e em casa com o cuidador. Os três grupos realizaram o mesmo protocolo de reabilitação, e antes e depois das 22 semanas de tratamento foram avaliados pelos mesmos instrumentos. Os resultados indicaram que as sessões em grupo são mais eficientes para sintomas psiquiátricos; individual para atividades da vida diária; e em casa
APA, Harvard, Vancouver, ISO, and other styles
25

Lee, David. "Age-Related Differences in In-vitro Sensitivity to Inhibition of Human Red Blood Cell Acetylcholinesterase and Plasma Butyrylcholinesterase by the Cholinesterase Inhibitors Physostigmine (PHYS), Pyridostigmine (PYR), Donepezil (DON) and Galantamine (GAL)." VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1937.

Full text
Abstract:
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder, characterized clinically by a progressive loss of memory, cognitive function, ability to care for oneself and psychiatric symptoms. First-line agents for the treatment of AD are ChE inhibitors (DON, GAL), whose modest clinical efficacy and the high incidence of dose-limiting toxicities limit their clinical utility. In addition to AD, ChE inhibitors (PYR) are used for other medical conditions, such as myasthenia gravis (MG). Furthermore, ChE inhibitors (PYR) are used by military personnel prophylactically if impendin
APA, Harvard, Vancouver, ISO, and other styles
26

Behl, Pearl. "Differential long-term cognitive, functional, and behavioral effects of cholinesterase inhibitors in Alzheimer's disease." 2006. http://link.library.utoronto.ca/eir/EIRdetail.cfm?Resources__ID=449939&T=F.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Bailey, Jack. "An analysis of modifiable risk factors, genetic underpinnings, and current medications for Alzheimer's disease." Thesis, 2018. https://hdl.handle.net/2144/33007.

Full text
Abstract:
Alzheimer’s disease (AD) is a widespread neurodegenerative disorder that affects tens of millions of patients worldwide. Throughout the last two decades an incredible amount of time and resources have been funneled into hopefully finding medications that would provide a cure. Unfortunately, no such compound has been identified and instead the only FDA approved medications for AD to date target symptomatic management and may not even be effective for longer than a couple of years. To this end, this paper sets out to identify modifiable risk factors for AD as well as provide recommendations for
APA, Harvard, Vancouver, ISO, and other styles
28

"High-level expression of recombinant acetylcholinesterase in silkworm larvae for screening of new inhibitors treating Alzheimer's disease." 2012. http://library.cuhk.edu.hk/record=b5549119.

Full text
Abstract:
乙酰膽鹼酯酶主要存在於神經肌肉接頭處和中樞神經系統的膽鹼能突觸處，是神經遞質傳遞過程中極其重要的膽鹼水解酶。研究表明，阿茲海默病人的大腦通常呈現出乙酰膽鹼酯酶的異常表達和分佈，並伴隨著β澱粉樣蛋白的沉澱。目前，乙酰膽鹼酯酶抑製劑是治療阿茲海默症的主要臨床藥物。<br>在本研究中，我們利用Bac-to-Bac 桿狀病毒表達系統分別使人類和雞泡魚的重組乙酰膽鹼酯酶基因在家蠶幼蟲裡得到了高效的表達。我們將乙酰膽鹼酯酶的cDNA序列克隆到pFastBac{U+2122} Dual質粒的多角體蛋白啟動子下游。為了易於監控蛋白表達水平，橙色熒光蛋白的cDNA序列也被克隆到同一個質粒的p10啟動子下游。此外，我們將多聚組氨酸標籤加在了乙酰膽鹼酯酶基因的碳端，從而使蛋白的純化效率得到了顯著提高。我們通過皮下注射含有乙酰膽鹼酯酶的重組bacmid對五齡期的家蠶幼蟲進行了病毒轉染。感染後約4-7天，重組乙酰膽鹼酯酶在蠶蟲內成功得到了表達。酶促反應動力學研究表明，重組乙酰膽鹼酯酶的活性與來自相同物種的天然乙酰膽鹼酯酶基本相似。這種高效率、低成本、高產量的蛋白表達方法可以為我們提供大量的重組乙酰膽鹼酯酶，用於體外篩選治療阿茲海默症的乙酰膽鹼酯酶抑製劑。<br>隨著對阿茲海默症分子學水平上的進一步了解，研究提出乙酰膽鹼酯酶可能通過外周陰離子位點誘導β澱粉樣多肽聚集, 從而形成澱粉樣纖維。因此，理想的乙酰膽鹼
APA, Harvard, Vancouver, ISO, and other styles
29

"CNS target delivery of acetylcholine esterase inhibitors via intranasal administration: pilot studies with tacrine and Its dimers." 2013. http://library.cuhk.edu.hk/record=b5884375.

Full text
Abstract:
Qian, Shuai.<br>Thesis (Ph.D.)--Chinese University of Hong Kong, 2013.<br>Includes bibliographical references (leaves 265-294).<br>Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.<br>Abstract also in Chinese.
APA, Harvard, Vancouver, ISO, and other styles
30

Jantzi, Micaela. "Use of Medications for Management of Alzheimer’s Disease in Ontario’s Home Care Population." Thesis, 2010. http://hdl.handle.net/10012/5056.

Full text
Abstract:
Abstract Background: Home care is an important care setting for those with Alzheimer’s disease (AD). It provides support that allows individuals with AD to remain at home and may delay the transition to long-term care homes. Many clients with AD receive medications that are used for managing the symptoms of AD: cholinesterase inhibitors (ChEIs) and memantine. Ontario’s provincial drug benefit plan (ODB) provides subsidies for some of these medications based on specific clinical criteria. These AD medications are costly and can have significant side effects, so it is important to understand ho
APA, Harvard, Vancouver, ISO, and other styles
31

Mohamed, Tarek. "Design, Synthesis and Biological Evaluation of 2,4-Disubstituted Pyrimidine Derivatives: Multifunctional Candidates as Potential Treatment Options for Alzheimer’s Disease." Thesis, 2011. http://hdl.handle.net/10012/6183.

Full text
Abstract:
Alzheimer’s disease (AD) is a highly complex and rapidly progressive neurodegenerative disorder characterized by the systemic collapse of cognitive function and formation of dense amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). AD pathology is derived from the cholinergic, amyloid and tau hypotheses, respectively. Current pharmacotherapy with known anti-cholinesterases, such as Aricept ® and Exelon ®, only offer symptomatic relief without any disease-modifying effects (DMEs). It is now clear that in order to prevent the rapid progression of AD, new therapeutic treatments should targ
APA, Harvard, Vancouver, ISO, and other styles
32

Charbonneau, Claudie. "A retrospective study of cholinesterase inhibitors for Alzheimer's disease : the effect of cerebrovascular disease on patient outcomes and the impact of biases on the results." Thèse, 2010. http://hdl.handle.net/1866/4883.

Full text
Abstract:
Introduction: La démence peut être causée par la maladie d’Alzheimer (MA), la maladie cérébrovasculaire (MCEREV), ou une combinaison des deux. Lorsque la maladie cérébrovasculaire est associée à la démence, les chances de survie sont considérées réduites. Il reste à démontrer si le traitement avec des inhibiteurs de la cholinestérase (ChEIs), qui améliore les symptômes cognitifs et la fonction globale chez les patients atteints de la MA, agit aussi sur les formes vasculaires de démence. Objectifs: La présente étude a été conçue pour déterminer si la coexistence d’une MCEREV était associée avec
APA, Harvard, Vancouver, ISO, and other styles
33

O'Regan, Jordana. "Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting." Thesis, 2014. http://hdl.handle.net/1807/44051.

Full text
Abstract:
Cholinesterase inhibitors (ChEIs) are the first line pharmacotherapy for the symptoms of Alzheimer’s disease (AD). Though ChEIs offer modest cognitive benefits in early AD, literature addressing their continued use in severe AD is scarce. This study assessed the safety of discontinuing ChEIs in institutionalized moderate-severe AD patients. Twenty-six patients were randomized, double-blind to ChEI continuation or placebo for 8-weeks. Vitals, weight (kg) and adverse events (AEs) were monitored biweekly. Chi-square test revealed no significant association between semi-blinded treatment allocati
APA, Harvard, Vancouver, ISO, and other styles
34

"Study of neuroprotective effect of cryptotanshinone, an acetylcholinesterase inhibitor, in cell and animal models." Thesis, 2009. http://library.cuhk.edu.hk/record=b6074975.

Full text
Abstract:
Alzhemier's disease (AD) is a common form of dementia which is characterized by the deposition of amyloids in affected neurons and a cholinergic neurotransmission deficit in the brain. Current therapeutic intervention for AD is primarily based on inhibition of brain acetylcholinesterase (AChE) to restore the brain acetylcholine level. Cryptotanshinone (CT) is a diterprene which is extracted from the root of Salvia miltiorrhiza, an herb that is commonly prescribed in Chinese medicine to treat cardiovascular disease. The present study is aimed at verifying CT's property as an AChE inhibitor usi
APA, Harvard, Vancouver, ISO, and other styles
35

"Screening of traditional Chinese medicine for anti-Alzheimer's disease drugs." 2005. http://library.cuhk.edu.hk/record=b5896404.

Full text
Abstract:
by Wong Kin Kwan Kelvin.<br>Thesis submitted in: September 2004.<br>Thesis (M.Phil.)--Chinese University of Hong Kong, 2005.<br>Includes bibliographical references (leaves 91-101).<br>Abstracts in English and Chinese.<br>Acknowledgements --- p.i<br>Abstract --- p.ii<br>摘要 --- p.iv<br>Abbreviations --- p.x<br>List of Figures --- p.xiii<br>List of Tables --- p.xiv<br>Chapter Chapter 1 --- Intorduction --- p.1<br>Chapter 1.1 --- Alzheimer，s disease --- p.1<br>Chapter 1.2 --- Histopathological features --- p.1<br>Chapter 1.3 --- Tau protein pathology and AD --- p.4<br>Chapter 1.4 --- Tau
APA, Harvard, Vancouver, ISO, and other styles
36

Čábelová, Pavla. "Syntéza, biologické hodnocení a in silico studie 7-MEOTA-donepezilových inhibitorů cholinesteras." Master's thesis, 2014. http://www.nusl.cz/ntk/nusl-337367.

Full text
Abstract:
Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Pharmaceutical Chemistry and Drug Control Student: Pavla ábelová Supervisor: Assoc. Prof. RNDr. Veronika Opletalová, Ph.D. Supervisor specialist: PharmDr. Jan Korábe ný, Ph.D. Title of diploma thesis: Synthesis, biological evaluation and in silico studies in the series of novel 7-methoxytacrine-donepezile like compounds Alzheimer's disease (AD) is an irreversible neurodegenerative disorder of the brain characterized clinically by loss of memory, deterioration of activities of daily living and cognition. The pathol
APA, Harvard, Vancouver, ISO, and other styles
37

Yang, Yuan-Han, and 楊淵韓. "Evaluating the Therapeutic Response of Acetyl-cholinesterase Inhibitor in Alzheimer''s Disease." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/02642912644336345663.

Full text
Abstract:
博士<br>高雄醫學大學<br>醫學研究所<br>99<br>The prevalence and incidence of Alzheimer’s disease (AD) is increasing with aging. Pathological hallmarks for AD are mainly senile plaque, neurofibrillary tangle, and neuronal loss eventually. Currently the treatment of AD is mainly focused on acetyl-cholinesterase inhibitors(AChE-I)However, not every AD patient will respond to the treatment of AChE-I. Therefore, we conducted a study to measure and analyze the plasma concentration of AChE-I: donepezil in relation to the clinically therapeutic response. We have found that higher plasma concentration of doenepzil d
APA, Harvard, Vancouver, ISO, and other styles
38

Osman, Wesseem. "Design, Synthesis, and Evaluation of Tacrine-Based Derivatives: Potential Agents to Treat Alzheimer’s Disease." Thesis, 2013. http://hdl.handle.net/10012/7666.

Full text
Abstract:
With the incidence of Alzheimer’s disease (AD) growing worldwide and in Canada along with the growing economic and social burdens, the need for more effective therapies becomes of great importance. Since the discovery of AD, a number of proposed theories have arisen to explain the pathophysiology including the i) cholinergic theory, ii) oxidative stress pathways, and iii) metal ion imbalance. The major class of drug therapies to treat AD are cholinesterase inhibitors; however, the “one drug, one target” approach has not proven fruitful and generally becomes ineffective in later stages of disea
APA, Harvard, Vancouver, ISO, and other styles
39

Dhar, Devjani. "Rational Design of sym-Triazines For Multitarget-directed Modulation of Cholinesterases and Amyloid-beta in Alzheimer’s Disease." Thesis, 2013. http://hdl.handle.net/1807/35601.

Full text
Abstract:
Alzheimer’s disease (AD), a progressive age-related neurodegenerative disorder is characterized by impairments in memory and cognitive functions. The two main pathogenic hallmarks associated with the progression of this multifactorial disease include accumulation of amyloid-beta (Aβ) plaques and the deterioration of the cholinergic system in the brain. Using cost-effective synthetic procedures, mono-, di-, and tri- substituted sym-triazine derivatives incorporating acetylcholine substrate analogues and aromatic phenyl moieties were synthesized for the targeted modulation of Aβ aggregation and
APA, Harvard, Vancouver, ISO, and other styles
40

Vašíčková, Alžběta. "Alkaloidy Vinca minor L. a jejich biologická aktivita (inhibice lidských cholinesteras) V." Master's thesis, 2020. http://www.nusl.cz/ntk/nusl-412256.

Full text
Abstract:
Vašíčková A.: Alkaloids of Vinca minor L. and their biological activity (inhibition of human cholinesterases) V. Diploma thesis, Charles University, Faculty of Pharmacy in Hradec Králové, Department of Pharmaceutical Botany, Hradec Králové 2020. From the selected fraction VM 215-258 were isolated 3 alkaloids by flash chromatography followed, preparative thin layer chromatography and crystallization. Their structure was determined by mass spectroscopy, NMR and optical rotation, and the obtained data were compared with those in literature. Strictamine and minovincinine belong to alkaloids previo
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography